eNauka - pregled
Pregled prema Autor Mercadal, Santiago
Prikaz rezultata 1 do 4 od 4
| Godina | Naslov | Autor(i) | Tip rezultata | Mp-kat. |
|---|---|---|---|---|
| 2015 | Comparison of Subcutaneous and Intravenous Rituximab in the Maintenance Setting: Updated Safety Results of the Phase III Sabrina Study in Patients with Follicular Lymphoma | Davies, A; Mihaljevic, Biljana S  ; Mercadal, Santiago; Mihaylov, G; Leppa, S; Cotting, D; Munoz, FJ; Veenstra, K; Berthillon, N; Barrett, M;
MacDonald, D;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2017 | Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial | Davies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem;
Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David;
| Naučni članak | 21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+ |
| 2016 | Longer Term Efficacy and Safety of Subcutaneous Compared with Intravenous Rituximab: Updated Results of the Phase 3 SABRINA Study | Davies, Andrew J; Mihaljevic, Biljana S ; Mercadal, Santiago; Mihaylov, Georgi; Leppa, Sirpa; Cotting, Denise; Veenstra, Klaas; Zharkov, Artem; Dixon, Mark; Barrett, Martin;
Macdonald, David;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |
| 2014 | Subcutaneous Rituximab and Chemotherapy Achieves Similar Overall Response Rates to Intravenous Rituximab in First-Line Follicular Lymphoma: Efficacy and Safety Results of the Phase Iii Sabrina Study | Davies, A; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Cambon, N; Macgregor, L; Brewster, M;
Barrett, M; MacDonald, D;
| Konferencijski rad | Mp kategorija će biti prikazana naknadno. |